Healthcare investment banking interview questions, with answers

Healthcare investment banking interviews mix the standard banking technicals with sector questions: how to value a drug with no sales yet, what a patent expiry does to a forecast, how payor mix drives a provider's revenue and why buyers pay with milestones and earn-outs. You also get fit questions on why healthcare and why this group, plus a deal to discuss. Timing varies by bank. Leerink Partners, for example, says interviews for its 2028 Summer Analyst Program will be conducted in January 2027.

Updated

The question types, with an example of each

Expect five kinds of questions. The healthcare ones follow the way banks split the sector. Leerink Partners, an investment bank specializing in healthcare, organizes its banking pages into Biopharma, Healthcare Services, and MedTech, Tools & Diagnostics. Learn how each one makes money before the interview, because most sector questions are business-model questions in disguise.

The question types and one example of each

The question types and one example of each
Question typeWhat it testsExample question
Standard technicalAccounting, DCF, comps, M&A and LBO mechanicsWalk me through a DCF.
Healthcare technicalThe valuation tools the sector needsHow would you value a biotech with one drug in Phase 2?
Sector and marketWhether you know how each sub-sector earns moneyHow does payor mix affect a physician group's revenue?
DealWhether you follow the market and can explain why a deal happenedTell me about a healthcare deal you've followed.
FitYour motivation and your storyWhy healthcare, and why our group?

Healthcare technical questions, answered

Each answer below is written by our team. Say each one out loud until you can give it in about a minute without notes. The table shows which metrics to mention in each sub-sector.

  • How would you value a pre-revenue biotech? Build a risk-adjusted NPV (rNPV) for each drug in the pipeline. Forecast the trial costs and, if the drug is approved, its sales and profits through patent expiry. Multiply each year's cash flow by the chance the drug is still alive that year, discount at the cost of capital and add up the drugs. Then add net cash, because many biotechs hold cash from their last raise. Cross-check against comparable companies and acquisitions of similar-stage assets.
  • How is rNPV different from a DCF? A plain DCF assumes the forecast happens and puts all the risk in the discount rate. rNPV puts the chance of failure into the cash flows, phase by phase, and then uses a normal discount rate. A very high discount rate on top of the probabilities counts the same risk twice.
  • Why can a biotech with no revenue be worth billions? The market is pricing future profits from drugs that may be approved, weighted by their odds. One approved drug can earn large profits for years before its patents expire, and the company's cash also counts toward equity value.
  • How does a patent expiry change a DCF? Once a drug loses exclusivity, generics (for small-molecule drugs) or biosimilars (for biologics) enter and its revenue falls. Model that decline, and don't put a perpetuity growth terminal value on the peak year. Run the forecast past the expiry or base the terminal value on the lower run rate after it. This is also why pharma companies with big expiries ahead buy biotechs: they need revenue to replace what they will lose.
  • What is EBITDAR and when do you use it? It is EBITDA before rent. Many providers lease their sites, and rent is deducted before EBITDA, so two providers that differ only in owning or leasing their buildings look different on EBITDA. EBITDAR removes that gap. Pair it with a lease-adjusted debt ratio: debt plus capitalized lease obligations, divided by EBITDAR.
  • A large pharma company buys a pre-revenue biotech. Accretive or dilutive? Dilutive to EPS at first, almost however it is paid for. The target adds losses, and the buyer gives up interest on its cash, pays interest on new debt or issues new shares. It accepts this because it is paying for revenue several years out. The quick P/E rule for all-stock deals doesn't help here, because a target with no earnings has no meaningful P/E.
  • How does a private equity roll-up in healthcare services make money? The firm buys a platform company, adds smaller practices or clinics at lower multiples, combines their back offices and negotiates with payors as a bigger group. Returns come from EBITDA growth, debt paydown and selling the larger company at a higher multiple than the add-ons cost. Name the risks too: reimbursement cuts, labor costs and antitrust review.

Which metrics to mention by sub-sector (our summary)

Which metrics to mention by sub-sector (our summary)
Sub-sectorMetrics to mentionWhy
Large pharmaP/E, EV/EBITDA, a DCF with patent expiries modeledSteady profits, but each product's revenue drops at loss of exclusivity
Pre-revenue biotechrNPV for each drug, plus net cashNo earnings or EBITDA to put a multiple on
Commercial-stage biotechEV/Revenue, rNPV for the pipelineRevenue is growing faster than profit
MedTechEV/Revenue, EV/EBITDADevice sales and margins, with growth from new products
Life science tools and diagnosticsEV/EBITDA, EV/RevenueRepeat sales of consumables and tests
Healthcare services and providersEV/EBITDA, EV/EBITDAR, same-store growth, payor mixLeased sites, and revenue that depends on who pays
Managed care (payors)P/E, medical loss ratioInsurers collect premiums and pay claims, so the share spent on care drives margin

Worked example: rNPV for one Phase 2 drug

An interviewer may hand you numbers and ask for an rNPV out loud. Our team wrote this example for practice. The drug, costs, sales and probabilities are made-up inputs, not industry success rates.

The setup: a biotech's only drug is about to start Phase 2. Assume a 50% chance it passes Phase 2, then a 50% chance it passes Phase 3, then an 80% chance the FDA approves it. So the chance of paying for Phase 3 is 50%, the chance of reaching the filing is 25% (50% x 50%) and the chance of reaching the market is 20% (25% x 80%). Use a 10% discount rate, because the probabilities already carry the trial risk.

Add up the present values. The costs total minus $44.9 million and the sales total plus $91.7 million, so the rNPV is about $46.8 million. Run the same cash flows as if success were certain and the NPV becomes about $382.8 million. That gap is your answer to "why not just use a DCF?" (Both figures are our calculations from the table.)

Expect two follow-ups. First, what happens if Phase 2 succeeds? Years 1 and 2 become 100%, Year 3 becomes 50% and Years 4 to 6 become 40%, and by our math the rNPV rises to about $111.7 million. That jump is why biotech share prices move on trial readouts. Second, what if the drug loses exclusivity after Year 6? Then the sales line drops after Year 6 instead of holding at $300 million. That drop is the patent cliff showing up in the model.

rNPV of an invented Phase 2 drug, in $ millions (our example)

rNPV of an invented Phase 2 drug, in $ millions (our example)
YearWhat happensNet cash flow ($M)ProbabilityRisk-adjusted ($M)Discount factor at 10%Present value ($M)
1Phase 2 trial-20100%-20.00.9091-18.2
2Phase 3 trial-6050%-30.00.8264-24.8
3FDA filing and launch prep-1025%-2.50.7513-1.9
4Launch year profit15020%30.00.683020.5
5Profit from sales30020%60.00.620937.3
6Profit from sales30020%60.00.564533.9

Sector questions: trials, financing, payors and regulators

Know the drug development path well enough to say what each step does to value. Phase 1 tests safety in a small group of people. Phase 2 looks for the right dose and a first sign that the drug works. Phase 3 runs larger trials to confirm it. The company then files a New Drug Application (NDA) for a small-molecule drug or a Biologics License Application (BLA) for a biologic, and the FDA decides. Each successful step raises value because the odds of reaching the market go up.

That long path is why biotech questions often turn to financing. Leerink's biopharma page puts it this way: "Having a reliable, ongoing source of capital is key to funding the lengthy process of bringing therapies to market." The same page lists two recent follow-on offerings, one for $150 million and one for $125 million, plus a $30 million PIPE. A follow-on is a public offering marketed widely to investors. A PIPE is a private sale of a public company's shares to a small group of investors, and it usually happens faster and with less marketing.

For providers, revenue per visit depends on who pays: commercial insurers, Medicare (the federal program mainly for older adults), Medicaid (run by states with federal funding, for people with low incomes) or the patient. Payor mix is the share of visits or revenue from each payor. Value-based care ties part of the payment to outcomes and total cost instead of to each service.

Here is a quick payor mix example with rates our team made up. A clinic is paid $150 a visit by commercial insurers and $100 a visit by Medicare and Medicaid. If 60% of visits are commercial, the blended rate is $130 (0.6 x $150 + 0.4 x $100). If the commercial share drops to 50%, the blended rate falls to $125 (0.5 x $150 + 0.5 x $100). That is about 3.8% less per visit with no change in volume, or $50,000 less revenue on 10,000 visits a year. Leerink's healthcare services page points to rising brick-and-mortar operational expenses and talent shortages, so a falling rate per visit plus rising wages squeezes margins from both sides.

For MedTech and tools, expect questions on how these companies depend on drug developers. Leerink's MedTech, Tools & Diagnostics page says new technologies are transforming early detection, and it calls the sector a trusted outsourcing partner for Biopharma.

Two kinds of review come up often. The FDA decides whether a drug or device can be sold, so approval risk shows up in both the price and the deal structure. Antitrust review can slow down or block mergers between competitors, such as two hospital systems in the same area. Be ready to explain how that risk affects the timeline and terms such as a reverse termination fee.

Deal terms and deals you can talk about

When an interviewer asks about a deal, answer in this order: who bought what, the price and how it was paid, why the buyer wanted the business, why the price made sense and the main risk. If the headline value says "up to," separate the money paid at closing from the money that depends on milestones.

The deals in the table come from Leerink Partners' site, where its bankers list transactions they advised on. Read the announcements before you bring one up. Then add one recent deal you found yourself, in the sub-sector of the group you're interviewing with.

Deal structure is where healthcare differs most. Leerink lists a pending sale of substantially all of a company's assets to CorMedix for about $223M upfront, plus up to $55M in earn-out payments, plus royalties. By our calculation from that listing, the upfront and the maximum earn-out add up to about $278M before royalties, and about 80% of that is paid upfront. Be ready to explain each piece of a deal like that:

  • Upfront payment: cash paid at closing. It is the only part the seller is sure to get.
  • Milestone payments: fixed amounts paid if certain events happen, such as a trial result or an approval. They move risk from the buyer to the seller.
  • Earn-outs: payments tied to how the asset performs after the deal, often its sales.
  • Contingent value rights (CVRs): rights given to a public target's shareholders that pay out if a stated event happens by a deadline. They do the job of milestone payments in a public deal.
  • Royalties: a percentage of future sales paid to the seller or licensor. A company can also sell a royalty stream for cash. Leerink's head of debt capital markets covers royalty monetization and structuring, among other products.
  • Licensing: the owner keeps the drug but grants rights to it, often for a single region, in return for upfront, milestone and royalty payments.

Public healthcare deals to practice with (values as listed by Leerink, notes ours)

Public healthcare deals to practice with (values as listed by Leerink, notes ours)
DealValue as listedSub-sector (our label)What to be ready to explain (ours)
Amgen acquires Horizon Therapeutics$27.3 billion, the largest life sciences transaction of 2022BiopharmaHow a buyer justifies and pays for a price this size
CSL acquires Vifor$11.7 billion, the largest life sciences transaction of 2021BiopharmaStrategic fit and the issues in a cross-border deal
Mylan and Upjohn combine$50 billion, closed in 2020PharmaWhy the companies combined instead of one paying cash for the other
Danaher acquires Abcam$5.7bnLife science toolsWhat a tools buyer gains by adding product lines
Novartis acquires CalypsoUp to $425mmBiopharmaWhy the price says "up to" and how much depends on milestones
Sale to HealthSpan Partners, an affiliate of Bon Secours Mercy Health$5.7 billion, pendingHealthcare servicesWhat a pending provider deal still needs, including antitrust review
Sale of substantially all assets to CorMedixAbout $223M upfront plus up to $55M in earn-out payments plus royalties, pendingBiopharmaWhy the deal is an asset sale and how the earn-out and royalties work
Galderma IPO$17bnEquity capital marketsWhy a company lists its shares instead of selling itself

Fit questions: why healthcare, why this group

Healthcare groups ask the usual banking fit questions with the sector added on top. Prepare these before your first call.

For "why this group," use something specific from the bank's own pages. Leerink's careers page says the firm is consistently one of the Top Five investment banking firms for healthcare transactions, citing FactSet and Dealogic. A November 13, 2026 release says the firm has advised on $105 billion in M&A since inception and helped clients raise over $230 billion. The same release announces a new Head of Healthcare Information Technology who reports to the Head of Healthcare Services. A detail like that lets you connect what the group is building to what you want to learn.

A science degree is one way in, not the only one. At Leerink, one co-president is a graduate of Harvard Medical School, and the other holds a B.A. in Economics and an MBA. Other senior bankers hold degrees in physics, electrical engineering and finance. If you don't have a science background, say how you learned the basics, such as trial phases, FDA filings and reimbursement, and then show that knowledge in your technical answers.

  • Why healthcare?
  • Why banking instead of consulting or a job at a drug or device company?
  • Why our group, and which sub-sector interests you most?
  • Tell me about a healthcare deal or trend you're following.
  • Walk me through your resume.
  • You don't have a science background. How will you keep up?

When interviews happen, and a two-week prep plan

Summer analyst recruiting starts early. Leerink Partners' careers page says applications are now open for its 2028 Summer Analyst Program, targeted towards current sophomores, and that interviews will be conducted in January 2027. The program lasts ten weeks and is for accomplished students in their penultimate year of undergraduate studies. The page also lists full-time openings, including Investment Banking Associate, Healthcare, and Investment Banking Analyst, Biopharma. Each bank sets its own calendar and format, so check its careers page and your invitation email for the number of rounds and who you will meet.

Our team wrote this plan for a candidate who already knows some finance and has about an hour a day. If your interview is sooner, shorten each step but keep the order.

  • Days 1 to 3: Rebuild the standard technicals out loud: accounting, the three statements, DCF, comps, precedents, accretion and dilution, and a simple LBO.
  • Days 4 and 5: Write one paragraph each on how biopharma, services, MedTech and tools companies make money, and which metrics you would quote.
  • Days 6 and 7: Rework the rNPV example above by hand. Change one input at a time (a trial probability, the discount rate, the year of patent expiry) and explain what moves.
  • Day 8: Practice the payor mix, EBITDAR and accretion questions with your own made-up numbers.
  • Days 11 and 12: Research the bank's sector pages, recent transactions and news for your "why this group" answer. Then write, say and time your "why healthcare" and "walk me through your resume" answers.
  • Days 13 and 14: Run full mock interviews that mix technicals, a deal and fit questions, then redo every answer you stumbled on.
Where healthcare bankers come from and go

Healthcare groups exist at both large banks and specialist firms. The bios of Leerink's senior bankers list earlier roles in healthcare groups at Citigroup, Merrill Lynch, Bank of America, J.P. Morgan, Credit Suisse, UBS, Guggenheim Securities, Jefferies, Lazard, Wells Fargo Securities and Piper Sandler. Its new Head of Healthcare Information Technology joined from Harris Williams, where he set up the Healthcare Information Technology practice in 2010.

People also move between banking and the industry, in both directions. One senior banker spent eight years at Merck and Pfizer before banking. Another was Deputy Head of Pharma M&A at Novartis. A third joined from Regeneron's corporate finance team, and a fourth worked in HCA's Corporate Finance and Development group. If you are asked about long-term goals, corporate development at a drug or provider company is one path these bios show.

Leerink describes itself as a broker-dealer registered with the SEC and a member of FINRA. Form BD is the SEC's Uniform Application for Broker-Dealer Registration, which broker-dealers file to register with the SEC, the self-regulatory organizations and the jurisdictions, through the Central Registration Depository system operated by FINRA. For the broader occupation of financial analysts, the Bureau of Labor Statistics says a bachelor's degree is the typical requirement to enter.

From Leerink Partners: Investment Banking, Leerink Partners: Careers, Leerink Partners: Biopharma, Leerink Partners: Healthcare Services, Leerink Partners: MedTech, Tools & Diagnostics, Leerink Partners: Head of Healthcare Information Technology appointment, November 13, 2026, US SEC: Form BD, Uniform Application for Broker-Dealer Registration and US Bureau of Labor Statistics: Financial Analysts, Occupational Outlook Handbook.

1 practice question and sample answer

Say your answer out loud first, then read the sample answer.

Practice question

  1. Why do you want to work in healthcare investment banking?

    Sample answer. Example answer written by our team. The applicant is invented. I came to healthcare through numbers, not a lab. I'm an economics major, and a class project on how hospital systems pay for new buildings got me hooked. I didn't expect the same patient visit to be worth such different amounts depending on who pays. After that I started reading deal announcements. Amgen's $27.3 billion acquisition of Horizon Therapeutics stuck with me because it was the largest life sciences deal of 2022, and I wanted to know how a buyer gets comfortable paying that much. What I like about healthcare valuation is that it makes you think about probability and timing, not just multiples. With an rNPV you have to say out loud how likely a trial is to work, and I enjoy that kind of judgment call. I want a group where deals depend on the science and the reimbursement as much as the financing. I don't have a science degree, so I've been teaching myself trial phases and FDA filings, and I'd keep doing that on the job.

    It opens with a concrete reason instead of a general love of healthcare. It names a real deal and the question that deal raised for the applicant. It shows the applicant knows what makes healthcare valuation different, and it deals with the missing science background directly by saying what they are doing about it.

Practice the interview, out loud

Soreno's AI interviewer asks banking fit and technical questions, follows up on your answers and scores them.

Questions people ask

Do you need a science background for healthcare investment banking?

No single path is required. At Leerink Partners, one co-president is a Harvard Medical School graduate and the other holds a B.A. in Economics and an MBA, and its summer program is for accomplished students in their penultimate year of undergraduate studies.

When do healthcare investment banking summer analyst interviews happen?

It depends on the bank. Leerink Partners says applications are open for its 2028 Summer Analyst Program, targeted towards current sophomores, and that interviews will be conducted in January 2027.

What is rNPV in a healthcare interview?

rNPV is a DCF in which each year's cash flow is multiplied by the chance the drug is still alive that year, and the result is discounted at a normal rate. Interviewers use it to test how you value biotechs that have no revenue yet.

Which technical topics are specific to healthcare?

Prepare rNPV, patent expiries and their effect on a DCF, EBITDAR for lease-heavy providers, payor mix and reimbursement, and deal terms such as milestones, earn-outs, CVRs and royalties. You still need the standard accounting, DCF, comps and M&A answers as well.

What healthcare deals should I know for an interview?

Know two well: one large public deal and one recent deal in the sub-sector of the group you're interviewing with. Large examples from Leerink's site include Amgen's $27.3 billion acquisition of Horizon Therapeutics and CSL's $11.7 billion acquisition of Vifor.

Keep going